Trial reportActa neurologica Belgica2021
Is gabapentin effective in dry eye disease and neuropathic ocular pain?
Trial report in Acta neurologica Belgica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Aqueous-deficient dry eye disease: Preferred practice pattern guidelines on clinical approach, diagnosis, and management.Indian journal of ophthalmology · 2023Guideline
- Risk of Incident Dry Eye Disease Among Patients With Chronic Pain Conditions.American journal of ophthalmology · 2026Article
- A Scoping Review of Pharmacologic and Nonpharmacologic Interventions to Treat Chronic Ocular Pain.Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society · 2026Article
- Management of Dry Eye Disease Pre- and Post-Cataract Surgery: A Personalized Approach.Journal of personalized medicine · 2026Review
- Integrated management of dry eye-depression comorbidity: mechanistic insights and temporal therapeutic strategies.Frontiers in medicine · 2026Article
- Severe Aqueous-Deficient Dry Eye Following Herpes Zoster Ophthalmicus With Periocular Inflammation: A Case Series.Cureus · 2025Article
- Navigating the Dry Eye Therapeutic Puzzle: A Mechanism-Based Overview of Current Treatments.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Corneal neuropathic pain: a review to inform clinical practice.Eye (London, England) · 2024Review
- Molecular Mechanisms and Therapeutic Potential of Gabapentin with a Focus on Topical Formulations to Treat Ocular Surface Diseases.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Association between systemic medication use and severity of dry eye signs and symptoms in the DRy eye assessment and management (DREAM) study.The ocular surface · 2024Article
- Aquaporins in the Cornea.International journal of molecular sciences · 2024Review
- Inflammation mechanism and anti-inflammatory therapy of dry eye.Frontiers in medicine · 2024Review
- Effects of Mirogabalin on Hyperalgesia and Chronic Ocular Pain in Tear-Deficient Dry-Eye Rats.Investigative ophthalmology & visual science · 2023Article
- Ion channels in dry eye disease.Indian journal of ophthalmology · 2023Review
- Neuropathic ocular surface pain: Emerging drug targets and therapeutic implications.Expert opinion on therapeutic targets · 2022Review
- Opioids and Ocular Surface Pathology: A Literature Review of New Treatments Horizons.Journal of clinical medicine · 2022Review
- Long-Term Trigeminal Nerve Stimulation as a Treatment for Ocular Pain.Neuromodulation : journal of the International Neuromodulation Society · 2021Article
- Could contact lens dryness discomfort symptoms sometimes have a neuropathic basis?Eye and vision (London, England) · 2021Review
- Topical TRPM8 Agonist for Relieving Neuropathic Ocular Pain in Patients with Dry Eye: A Pilot Study.Journal of clinical medicine · 2021Article
- Effects of Topical Gabapentin on Ocular Pain and Tear Secretion.Frontiers in pharmacology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to evaluate the efficacy of gabapentin treatment in dry eye disease (DED) and neuropathic ocular pain. Our study was performed with 72 patients. The painDETECT questionnaire was used for neuropathic pain screening. Patients who were thought to have severe DED according to ocular surface disease index (OSDI) questionnaire, Schirmer's test type 1 and tear break up time test results were treated with artificial tear and cyclosporine drops. Gabapentin treatment was also initiated in addition to artificial tear and cyclosporine drops treatments to the patients with neuropathic component and DED findings. We divided the patients into two groups: group 1 (n: 36), patients treated with artificial tear and cyclosporine drops and group 2 (n: 36), patients treated with artificial tear, cyclosporine drops and gabapentin. In the first evaluation, no significant differences were found between groups in terms of OSDI score, Schirmer's test result and TBUT. After the 6 weeks of treatment, in both groups OSDI score, Schirmer's test result and TBUT statistically significantly improved. OSDI score, Schirmer's test result and TBUT significantly improved after the 6 weeks of gabapentin treatment than artificial tear and cyclosporine treatment group (p < 0.001). Dry eye patients should be screened for neuropathic ocular pain symptoms and individualized treatment has to be applied. Our study showed that the use of gabapentin is effective in severe dry eye patients with neuropathic ocular pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.